Treysta Medical Technologies Secures NSF Funding to Advance Scar-Prevention Burn Care Therapy
Treysta Medical Technologies Inc., a Gainesville, Florida–based medical technology startup focused on regenerative healing and scar-mitigation therapies, has secured early-stage funding support to advance the development of its proprietary burn care and wound-healing technology. Founded in 2025, the company is working to address one of the most persistent challenges in trauma and surgical recovery: preventing fibrotic scarring while promoting healthy tissue regeneration.
The company received a $304,984 Small Business Innovation Research (SBIR) Phase I grant from the National Science Foundation, providing non-dilutive funding to support the feasibility and validation of its novel therapeutic system. The award is intended to fund early research and development efforts focused on creating a new burn care therapy designed to prevent fibrotic pathologies, a common complication that can severely impact patient outcomes following serious burn injuries.
The funded project centers on the development of an integrated therapeutic approach that combines anti-scarring compounds with advanced wound dressing technology. Treysta’s system is designed to guide the body’s natural healing process, aiming to reduce excessive collagen formation that leads to raised or rigid scars. By addressing both biological and mechanical aspects of wound healing, the company is seeking to improve functional recovery while also reducing long-term cosmetic damage.
As part of the SBIR Phase I program, Treysta plans to complete a series of preclinical studies to demonstrate proof of concept and technical feasibility. These efforts include in vivo testing to evaluate how effectively the therapy prevents fibrosis and supports healthy tissue repair. Successful completion of this phase is expected to position the company for future development milestones, including potential Phase II funding and broader clinical validation.
Treysta Medical Technologies is led by co-founders Nathan Zarnstorff, Chief Executive Officer, and Marcelo Buzzi, Ph.D., Chief Scientific Officer. The founding team brings experience in medical device innovation, regenerative medicine, and early-stage technology commercialization. Their shared vision is to transform the standard of care in wound management by shifting the focus from scar treatment after healing to proactive scar prevention during the healing process.
In addition to burn care, Treysta’s technology platform has potential applications across a wide range of surgical and traumatic wounds. The company is exploring opportunities to adapt its therapy for use in procedures where scarring can have lasting physical or psychological effects, including reconstructive surgeries and routine surgical interventions. This broader applicability could expand the commercial potential of the company’s platform as development progresses.
The SBIR grant represents the first publicly disclosed funding milestone for Treysta and reflects growing interest in solutions that address unmet needs in regenerative medicine. Non-dilutive federal funding is particularly valuable for early-stage medical technology companies, as it allows them to advance research and development without giving up equity or control. The award also serves as external validation of the scientific and technical merit of Treysta’s approach.
With the support of the National Science Foundation, Treysta Medical Technologies is now positioned to advance its research toward key developmental benchmarks. The company expects that progress achieved during the Phase I program will help lay the groundwork for future funding opportunities, strategic partnerships, and regulatory planning as it works toward bringing its scar-prevention therapies closer to clinical use.
